Combined inhibition of PDE4 and PI3Kδ Modulates the inflammatory component involved in the progression of chronic obstructive pulmonary disease

Drug Research

Volumn 64, Issue 4, 2014, Pages 214-219

  Dinavahi, S S ^a   Nyayapathy, S ^b   Perumal, Y ^a   Dharmarajan, S ^a   Viswanadha, S ^b  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b SP Biotech Park   (India)

Author keywords

COPD; IC87114; PDE4; PI3K; Roflumilast

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; CIGARETTE SMOKE; GELATINASE B; LEUKOCYTE ELASTASE; LIPOPOLYSACCHARIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE IV; PROTEIN KINASE B; ROFLUMILAST; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS EPITHELIUM; MACROPHAGE; NEUTROPHIL; PROTECTION;

ADENINE; AMINOPYRIDINES; BENZAMIDES; CELL LINE, TUMOR; CYCLOPROPANES; DISEASE PROGRESSION; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MATRIX METALLOPROTEINASE 9; NEUTROPHILS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHODIESTERASE 4 INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PULMONARY ALVEOLI; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINAZOLINES; SMOKE; TOBACCO; U937 CELLS;

EID: 84897968944     PISSN: 21949379     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0033-1355411     Document Type: Article

References (27)

1. Barnes P. J. Mechanisms of COPD: Differences from asthma. Chest: 2000; 117 10S 14S
2. Sandford A. J., Silverman E. K. Chronic obstructive pulmonary disease. Susceptibility factors for COPD the genotype-environment interaction. Thorax: 2002; 57 736 741
3. Conti M., Richter W., Mehats C. et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem: 2003; 278 5493 5496
4. MacIntyre N. R. Chronic obstructive pulmonary disease: Emerging medical therapies. Respir Care: 2004; 49 64 69
5. Barnes P. J. Theophylline for COPD. Thorax: 2006; 6 742 744
6. Rommel C., Camps M., Ji H. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol: 2007; 7 191 201
7. Sadhu C., Masinovsky B., Dick K. et al. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol: 2003; 170 2647 2654
8. Herman SE M., Gordon A. L., Wagner A. J. et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood: 2010; 116 2078 2088
9. Marwick J. A., Caramori G., Casolari P. et al. A role for phosphoinositol 3-kinase δ in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol: 2010; 25 1146 1153
10. Blue M. L., Janoff A. Possible mechanisms of emphysema in cigarette smokers: release of elastase from human polymorphonuclear leukocytes by cigarette smoke condensate in vitro. Am Rev Respir Dis: 1978; 17 317 325
11. Haslett C., Guthrie L. A., Kopaniak M. M. et al. Modulation of multiple neutrophil functions by preparative methods or trace concentrations of bacterial lipopolysaccharide. Am J Pathol: 1985; 119 101 110
12. Barnes P. J., Adcock I. M. Glucocorticoid resistance in inflammatory diseases. Lancet: 2009; 373 1905 1917
13. Nassr N., Huennemeyer A., Herzog R. et al. Gezim Lahu. Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Clin Pharmacol: 2009; 68 580 587
14. To Y., Ito K., Kizawa Y. et al. Targeting phosphoinositide-3-kinase- δ with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Critical Care Med: 2010; 182 897 904
15. Lou L., Urbani J., Ribeironeto F. et al. cAMP inhibition of Akt is mediated by activated and phosphorylated Rap1b. J Biol Chem: 2002; 277 32799 32806
16. Pugazhenthi S., Nesterova A., Sable C. et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem: 2002; 275 10761 10766
17. Smith P. G., Wang F., Wilkinson K. N. et al. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood: 2005; 105 308 316
18. Ojaniemi M., Glumoff V., Harju K. et al. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur J Immunol: 2003; 33 597 605
19. Kim S., Jee K., Kim D. et al. Cyclic AMP inhibits Akt activity by blocking the membrane localization of PDK1. J Biol Chem: 2001; 276 12864 12870
20. Manning B. D., Cantley L. C. Akt/PKB signaling: navigating downstream. Cell: 2007; 129 1261 1274
21. Barnes P. J. Alveolar macrophages as orchestrators of COPD. COPD: 2004; 1 59 70
22. Atkinson J. J., Senior R. M. Matrixmetalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol: 2003; 28 12 24
23. Li Y., Zhang Z., Xu Y. et al. TNF-alpha up-regulates matrix metalloproteinase-9 expression and activity in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Huazhong Univ Sci Technolog Med Sci: 2006; 26 647 650
24. Shapiro S. D. Neutrophil elastase: path clearer, pathogen killer, or just pathologic? Am J Respir Cell Mol Biol: 2002; 26 266 268
25. Segura-Valdez L., Pardo A., Gaxiola M. et al. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest: 2000; 117 684 694
26. Demedts I. K., Demoor T., Bracke K. R. et al. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res: 2006; 7 53 62
27. Hoshino Y., Mio T., Nagai S. et al. Cytotoxic effects of cigarette smoke extract on an alveolar type II cell-derived cell line. Am J Physiol Lung Cell Mol Physiol: 2001; 281 L509 L516